Summary
AG8 Chart
Don't Overlook Agilent (A) International Revenue Trends While Assessing the Stock
Explore how Agilent's (A) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Agilent Technologies, Inc. (A) Q2 2025 Earnings Conference Call Transcript
Agilent Technologies, Inc. (NYSE:A ) Q2 2025 - Earnings Conference Call May 28, 2025 4:30 PM ET Company Participants Parmeet Ahuja – VP, IR Padraig McDonnell - President and CEO Robert W. McMahon - SVP and CFO Simon May - President of Life Sciences and Diagnostics Markets Group Angelica Riemann - President of Agilent CrossLab Group Mike Zhang - President of Applied Markets Group Conference Call Participants Patrick Donnelly - Citi Jack Meehan - Nephron Research Rachel Vatnsdal - JPMorgan Puneet Souda - Leerink Partners Vijay Kumar - Evercore ISI Tycho Peterson - Jefferies Brandon Couillard - Wells Fargo Michael Ryskin - Bank of America Dan Leonard - UBS Operator Good afternoon.
Here's What Key Metrics Tell Us About Agilent (A) Q2 Earnings
While the top- and bottom-line numbers for Agilent (A) give a sense of how the business performed in the quarter ended April 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Agilent Technologies Inc. Dividends
 AG8 8 months ago | Other | €0.24 Per Share |
| AG8 11 months ago | Other | €0.24 Per Share |
| AG8 2 Apr 2024 | Other | €0.24 Per Share |
| AG8 29 Dec 2023 | Other | €0.24 Per Share |
| AG8 2 Oct 2023 | Other | €0.23 Per Share |
Agilent Technologies Inc. Earnings
| 19 Aug 2025 (77 Days) Date | | - Cons. EPS | - EPS |
| 28 May 2025 Date | | 1.26 Cons. EPS | 1.31 EPS |
| 27 May 2025 Date | | - Cons. EPS | - EPS |
| 25 Feb 2025 Date | | - Cons. EPS | - EPS |
| 25 Nov 2024 Date | | - Cons. EPS | - EPS |
| AG8 8 months ago | Other | €0.24 Per Share |
| AG8 11 months ago | Other | €0.24 Per Share |
| AG8 2 Apr 2024 | Other | €0.24 Per Share |
| AG8 29 Dec 2023 | Other | €0.24 Per Share |
| AG8 2 Oct 2023 | Other | €0.23 Per Share |
| 19 Aug 2025 (77 Days) Date | | - Cons. EPS | - EPS |
| 28 May 2025 Date | | 1.26 Cons. EPS | 1.31 EPS |
| 27 May 2025 Date | | - Cons. EPS | - EPS |
| 25 Feb 2025 Date | | - Cons. EPS | - EPS |
| 25 Nov 2024 Date | | - Cons. EPS | - EPS |
Agilent Technologies Inc. (AG8) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Agilent Technologies Inc. ever had a stock split?
Agilent Technologies Inc. Profile
| Medical - Diagnostics & Research Industry | Healthcare Sector | Mr. Padraig McDonnell CEO | XSTU Exchange | US00846U1016 ISIN |
| US Country | 17,900 Employees | 1 Jul 2025 Last Dividend | 3 Nov 2014 Last Split | - IPO Date |
Overview
Agilent Technologies, Inc. stands as a global provider offering application-focused solutions primarily to the life sciences, diagnostics, and applied chemical sectors. The company propagates its mission across three distinct segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab, ensuring a broad spectrum of scientific research, diagnostic, and analytical needs are met worldwide. Since its establishment in 1999, Agilent has cemented its headquarters in Santa Clara, California, from where it orchestrates its global operations, offering an expansive portfolio through direct sales, distributors, resellers, and electronic commerce frameworks.
Products and Services
- Life Sciences and Applied Markets: This segment includes a vast array of technologies such as liquid and gas chromatography systems and components, mass spectrometry systems, spectroscopy instruments, and various laboratory software solutions. It extends to capturing cell analysis with plate-based assays, flow cytometers, real-time cell analyzers, and cell imaging systems, supported by laboratory automation and robotic systems. The emphasis on quality is further underscored by their vacuum pumps and measurement technologies, ensuring precision and efficiency in research and diagnostic activities.
- Diagnostics and Genomics: Emphasizing the critical nature of genomics and nucleic acid research, this segment covers the bases from contract manufacturing to pathology and companion diagnostics. It spans a spectrum that includes reagent partnerships and biomolecular analysis, facilitating advanced diagnostics and extensive research capabilities in the genomic space. This commitment is aimed at pushing the boundaries of molecular diagnostics, providing comprehensive solutions for research and clinical applications.
- Agilent CrossLab: A testament to Agilent’s overarching commitment to support and service, the CrossLab segment provides an exhaustive list of laboratory instrument supplies, including GC and LC columns, sample preparation products, and custom chemistries. Beyond products, CrossLab’s service portfolio is robust, offering everything from repairs, parts, and maintenance to installations, training, and compliance support. With software as a service, asset management, and consulting services, this segment is designed to optimize laboratory operations and enhance the productivity and longevity of research investments.
Contact Information
